

Advancing care in rare melanocortin-4 receptor (MC4R) pathway diseases:

Focus on Bardet-Biedl syndrome (BBS)

Rhythm-sponsored promotional satellite symposium at European Congress on Obesity (ECO) 2026

DATE:
13 May 2026

TIME:
18:00–19:30 TRT

LOCATION:
Hall 2

SPEAKERS:



Professor Carel Le Roux
University College Dublin, Ireland



Professor Christine Poitou Bernert
GHU APHP/Sorbonne Université,
France



Professor Karine Clément
Pitié-Salpêtrière Hospital, Sorbonne
Université, France

TOPIC	SPEAKERS
Welcome and introduction	Prof. Carel Le Roux
Overview of rare MC4R pathway diseases as a root cause of hyperphagia and obesity	Prof. Carel Le Roux
Real-world evidence in treating BBS	Prof. Christine Poitou Bernert
Impact of early-onset obesity and urgency to treat	Prof. Karine Clément
Interactive Q&A session	All

This symposium is organised and funded by Rhythm Pharmaceuticals Netherlands B.V. for healthcare professionals only and includes promotional content on a licensed Rhythm Pharmaceuticals product.

Bu tanıtım materyali Türkiye'de görev yapan sağlık profesyonellerine yönelik değildir.

IMCIVREE™ (setmelanotide) Türkiye'de ruhsatlı değildir. Ürünün ruhsat durumu ülkelere göre farklılık gösterebilir. Reçetelmeden önce ülkenizdeki ilaç rehberine bakınız veya Rhythm Pharmaceuticals ile iletişime geçiniz.

This promotional material is intended for healthcare professionals only.

IMCIVREE™ (setmelanotide) is not licensed in Türkiye. Product licensing status may vary by country. Please consult your country's medicines guide or contact Rhythm Pharmaceuticals before prescribing.

CLICK HERE to access the SmPC. This medicine is subject to additional monitoring. Adverse events should be reported to Rhythm Pharmaceuticals on medinfo@rhythm.com.

© 2026, Rhythm Pharmaceuticals, Inc. All rights reserved. Rhythm and its logo are trademarks of Rhythm Pharmaceuticals, Inc.

INT-IC1-2600032 03/2026

Rhythm
PHARMACEUTICALS